Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Cordero

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Diseases (Basel, Switzerland)|October 25, 2024
Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized StudyJosé Seijas-Amigo, Maria José Mauriz-Montero, Pedro Suarez-Artime, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 4, 2013
[Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC for its Spanish acronym) on the 2012 European Cardiovascular Prevention Guidelines]Miguel Angel Royo-Bordonada, José María Lobos Bejarano, Fernando Villar Alvarez, et al.
Acta Diabetologica|September 13, 2021
Should PRECISE-DAPT be included for long-term prognostic stratification of diabetic patients with NSTEACS?Federico García-Rodeja Arias, Belén Álvarez Álvarez, Teba González Ferrero, et al.
Journal of Clinical Medicine|June 10, 2022
Antithrombotic Therapy in Elderly Patients with Acute Coronary SyndromesClara Bonanad, Francisca Esteve-Claramunt, Sergio García-Blas, et al.
Revista Espanola De Salud Publica|June 19, 2013
[Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC) on the 2012 European Cardiovascular Prevention Guidelines]Miguel Ángel Royo-Bordonada, José María Lobos Bejarano, Fernando Villar Alvarez, et al.
BMC Family Practice|March 20, 2013
Implementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary careCarlos Brotons, José Maria Lobos, Miguel Ángel Royo-Bordonada, et al.
Diabetes & Metabolic Syndrome|October 23, 2025
Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective studyJosé Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Dominguez, et al.
International Journal of Cardiology|December 23, 2021
Early angiography in elderly patients with non-ST-segment elevation acute coronary syndrome: The cardio CHUS-HUSJ registryTeba González Ferrero, Belén Álvarez Álvarez, Alberto Cordero, et al.
Clinical Therapeutics|May 8, 2026
Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)José Seijas-Amigo, Ángel Salgado-Barreira, Carlota Roca-Martinez, et al.
Plos One|September 28, 2018
Correction: Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK studyDomingo Orozco-Beltran, Vicente F Gil-Guillen, Josep Redon, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Diseases (Basel, Switzerland)|October 25, 2024
Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized StudyJosé Seijas-Amigo, Maria José Mauriz-Montero, Pedro Suarez-Artime, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 4, 2013
[Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC for its Spanish acronym) on the 2012 European Cardiovascular Prevention Guidelines]Miguel Angel Royo-Bordonada, José María Lobos Bejarano, Fernando Villar Alvarez, et al.
Acta Diabetologica|September 13, 2021
Should PRECISE-DAPT be included for long-term prognostic stratification of diabetic patients with NSTEACS?Federico García-Rodeja Arias, Belén Álvarez Álvarez, Teba González Ferrero, et al.
Journal of Clinical Medicine|June 10, 2022
Antithrombotic Therapy in Elderly Patients with Acute Coronary SyndromesClara Bonanad, Francisca Esteve-Claramunt, Sergio García-Blas, et al.
Revista Espanola De Salud Publica|June 19, 2013
[Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC) on the 2012 European Cardiovascular Prevention Guidelines]Miguel Ángel Royo-Bordonada, José María Lobos Bejarano, Fernando Villar Alvarez, et al.
BMC Family Practice|March 20, 2013
Implementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary careCarlos Brotons, José Maria Lobos, Miguel Ángel Royo-Bordonada, et al.
Diabetes & Metabolic Syndrome|October 23, 2025
Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective studyJosé Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Dominguez, et al.
International Journal of Cardiology|December 23, 2021
Early angiography in elderly patients with non-ST-segment elevation acute coronary syndrome: The cardio CHUS-HUSJ registryTeba González Ferrero, Belén Álvarez Álvarez, Alberto Cordero, et al.
Clinical Therapeutics|May 8, 2026
Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)José Seijas-Amigo, Ángel Salgado-Barreira, Carlota Roca-Martinez, et al.
Plos One|September 28, 2018
Correction: Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK studyDomingo Orozco-Beltran, Vicente F Gil-Guillen, Josep Redon, et al.
Pageof 20